An unselected series is presented of 17 infants born to epileptic mothers and exposed to sodium valproate during pregnancy. Nine infants had minor abnormalities and of these infants five also had major malformations, described as the 'fetal valproate syndrome'. The most frequent malformation was congenital heart disease. Nine of the infants had manifestations of withdrawal, such as irritability, jitteriness, abnormalities of tone, seizures, and feeding problems. Four of these infants had an unrelated hypoglycaemia. The frequency of withdrawal symptoms was significantly related to the dose of valproate given to the mothers in the third trimester, and there was a tendency for both the frequency of the minor abnormalities and the major malformations to be related to the valproate dosage in the first trimester.
The frequency of minor abnormalities and major malformations in infants of epileptic mothers is increased and associated with the epilepsy.' In addition, phenytoin given to pregnant women might increase the frequency of abnormalities and malformations, 'the fetal hydantoin syndrome'.2 Other antiepileptic drugs are suspected of having a teratogenic effect.
The teratogenic effect of valproate was observed in animals by Pinder et al,3 and a possible teratogenic effect has also been described in humans. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] It has been suggested that there is an association between valproate treatment during pregnancy and spina bifida in the fetus.5 6 12 Furthermore, some authors have postulated the existence of a 'fetal valproate syndrome', in which infants have minor abnormalities and major malformations to a variable degree.9 14 15 18 We present 17 infants born to 17 epileptic mothers who received sodium valproate as monotherapy or polytherapy during pregnancy. The purpose of this study is to draw attention to the high frequency of minor abnormalities and major malformations, the withdrawal manifestations, and hypoglycaemia in these infants.
Patients and methods
We studied all infants born to epileptic mothers treated with valproate as monotherapy or polytherapy during pregnancy in the North Jutland region of Denmark between 1 January 1987 and 31 December 1989. During this period 18 000 infants were born.
Seventeen mothers gave birth to 17 infants. Twelve mothers had primary generalised epilepsy and five complex partial epilepsy ( 13 17 Nine (53%) of the infants developed neurological manifestations including irritability, jitteriness, hypotonia, hypertonia (or variable tone), and feeding problems (table 2). Signs and symptoms began 12 to 48 hours after delivery, lasted from three days to four weeks and were treated with phenobarbitone. In four infants there were repeated seizures from day 2 to day 5. These infants were treated with diazepam. In all nine infants the serum calcium concentration was normal; four had hypoglycaemia during days 1-4 (blood glucose < 1-8 mmoll; table 2) but recorded signs were unrelated to the glucose concentration. Hypoglycaemia was treated with intravenous glucose infusion. In one case (number 14) the treatment was supplemented with glucagon and hydrocortisone.
Neurological symptoms were seen in eight of 11 infants born to mothers who received a daily valproate dose of 2-0 g or more in the third trimester, but only in one infant from six mothers who received less than 2-0 g valproate per day (p=0.03). On follow up at age 2-0-3-5 years, one child (number 1) was found to have slight, and two children (numbers 10 and 1 1) severe, psychomotor retardation. No infants had cerebral palsy.
Discussion
We present an unselected series of 17 Danish infants exposed to valproate during pregnancy. The daily dose given to several of the pregnant women was very high, in comparison with earlier studies. Nine of 17 pregnant women received a daily dose of -2-5 g, the highest being 6-6 g in the third trimester. High doses were often necessary to keep a constant plasma concentration because the free fraction of valproate increases during pregnancy with a consequent increase in renal excretion.
Contrary to other authors, we found no association between valproate treatment during pregnancy and intrauterine growth retardation9 10 13 Hypoglycaemia occurred in four of the nine infants in whom blood glucose concentrations were measured. One of the infants described by DiLiberti et al also had hypoglycaemia.9 However, the risk of developing hypoglycaemia cannot be known without systematic measurements of blood glucose concentrations in all infants.
The minor abnormalities as well as the major malformations were characteristic for the fetal valproate syndrome.9 14 15 18 There was a tendency for the frequency of abnormalities and malformations to be related to the valproate dose in the first trimester. JagerRoman et al found the same tendency,"1 although the highest dose they used was 2-0 g per day.
Previous authors have suggested a tendency towards an increase in the frequency of abnormalities and malformations in those epileptic mothers receiving valproate as part of polytherapy rather than monotherapy. We did not confirm this.
Retarded psychomotor development occurs frequently in children of epileptic mothers treated with valproate during pregnancy, as also described by other authors.9 14 15 We conclude that there is a tendency for fetal valproate syndrome, characterised by both minor abnormalities and major malformations, to be related to the dose in the first trimester, whether given as monotherapy or polytherapy. Increasing the dose during pregnancy increases the likelihood of withdrawal symptoms. We recommend as low a dose as possible to prevent seizures in the mother. As the risk of withdrawal symptoms is presumably related to the free fraction of plasma valproate, it seems appropriate to detect and maintain this fraction at a constant concentration. 
